The Priority Review

Tag

proximod

1 story

  1. Clinical trials

    Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis

    Jiankuan (Suzhou) Biotechnology Company Limited registered a Phase 3 trial of proximod for moderate-to-severe active rheumatoid arthritis. The study plans to enroll 590 participants and is expected to start on October 15, 2026.